ViroMed aims phase 1 trial on CAR-T cell therapy by 2020-2022 – Korea Biomedical Review
|
ViroMed aims phase 1 trial on CAR–T cell therapy by 2020-2022
Korea Biomedical Review ViroMed said it would conduct a phase 1 clinical trial on CAR-T (chimeric antigen receptor T–cell) therapy, a new cancer-targeting immunotherapy, in the U.S. market by 2020-2022. The Korea-based biotech venture last year entered into an exclusive … |
